Accesswire
23 Sept 2026, 10:30 UTC · 5h ago
Verdict
Headline takes no side. We score BDRX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Biodexa expects an interim futility analysis for the eRapa Phase 3 trial in Q1 2027.
Newinterview dated September 23, 2026
So whatThis creates a binary catalyst within 5 months that could either validate the program or lead to a total write-down of the lead asset.
More positive than 92% of claims this week
The Phase 3 Serenta trial is more than 50 percent enrolled with over 90 of 168 planned participants recruited.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newinterview dated September 23, 2026
So whatFull recruitment is targeted for H1 2027, meaning the company must secure the remaining 78 patients in approximately 6 months.
More positive than 63% of claims this week
The Phase 3 trial completion date is estimated between mid-2028 and the end of 2029.
Newinterview dated September 23, 2026
So whatThe wide 18-month window for the final readout increases the risk of a capital raise before commercialization.
More positive than 50% of claims this week
Biodexa has received $20 million in grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
Priced inno timing evidence for grant award
So whatNon-dilutive funding reduces the immediate need for equity financing to cover the remaining 78 patient enrollments.
More positive than 41% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company has a lead drug candidate in Phase 3 trials with orphan drug designations and $20 million in grant funding.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
11h ago
+5.0%
Price agrees with the score
$0.7149 vs $0.6810 close before publication (Sep 22) · not market-adjusted
BDRX chart →
